Related Experiment Video
Updated: Sep 10, 2025

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay
Published on: January 26, 2019
Current Challenges and Future Directions for RSV Prevention Strategies in Japan
Chikara Ogimi1, Tatsuki Ikuse1, Yuta Aizawa2
1From the Division of Infectious Diseases, Department of Medical Subspecialties, National Center for Child Health and Development, Tokyo, Japan.
Insights
Respiratory syncytial virus (RSV) causes severe infant infections. Japan
Area of Science:
- Pediatrics
- Infectious Diseases
- Public Health
Background:
- Respiratory syncytial virus (RSV) is a major cause of infant lower respiratory tract infections.
- RSV seasonality in Japan has shifted, with summer peaks now observed in northern regions like Hokkaido.
- New prevention tools, nirsevimab and a maternal vaccine, are now available in Japan.
Purpose of the Study:
- To analyze the changing epidemiology of RSV in Japan.
- To evaluate the accessibility and implementation challenges of new RSV prevention tools.
- To propose optimized, equitable strategies for infant RSV protection in Japan.
Main Methods:
- Analysis of RSV epidemiological data in Japan, noting seasonal shifts.
- Review of current policies and reimbursement structures for nirsevimab and maternal RSV vaccines.
- Development of a risk-based, season-independent prevention strategy proposal.
Main Results:
- RSV outbreaks in Japan, particularly Hokkaido, increasingly peak in summer, deviating from traditional winter patterns.
- Access to maternal vaccines is limited by out-of-pocket costs, and nirsevimab reimbursement is restricted to high-risk infants during the RSV season.
- A proposed strategy involves maternal vaccination after 28 weeks gestation and nirsevimab for unvaccinated or preterm infants.
Conclusions:
- Equitable access to RSV prevention in Japan requires policy and system-level improvements.
- Adapting implementation strategies to Japan's evolving RSV epidemiology is crucial for infant protection.
- Japan's experience offers valuable insights for global RSV prevention planning amidst changing transmission patterns.
Abstract:
Respiratory syncytial virus (RSV) remains a leading cause of lower respiratory tract infections in infants, particularly those under 6 months of age. In Japan, RSV seasonality in temperate regions has recently shifted from traditional winter peaks to more year-round circulation, with this change most pronounced in higher latitude areas such as Hokkaido, where outbreaks increasingly peak in summer. Japan has recently approved 2 RSV prevention tools: nirsevimab for infants and a maternal vaccine. However, challenges remain: maternal vaccines require out-of-pocket payment, and nirsevimab is reimbursed only for high-risk infants under national insurance and must be administered during the RSV season. These limitations call for policy and system-level improvements to ensure equitable access. A season-independent, risk-based prevention strategy-such as maternal vaccination at or after 28 weeks' gestation and nirsevimab for preterm or otherwise unvaccinated infants-may help optimize protection while minimizing overlap. Adapting implementation strategies to Japan's shifting epidemiology will be essential to efficiently protect all infants. Japan's experience may also provide insights for other countries facing changes in RSV transmission patterns and planning broader prevention approaches.
Related Concept Videos
Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Healthcare Associated Infections II: Preventive Measures
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
Rheumatic Heart Disease III: Medical Management
Coronary Artery Disease IV: Preventive Measures
Rheumatic Heart Disease IV: Nursing Management

